What is the recommended treatment for moderate dermatitis?

Treatment for Moderate Dermatitis

For moderate dermatitis, start with topical corticosteroids (TCS) as first-line therapy, combined with regular emollient use and trigger avoidance. 1, 2

First-Line Approach

Topical Corticosteroids

• TCS are the cornerstone of treatment for moderate dermatitis flares 1, 2
• Use medium-potency TCS for body areas, lower potency for face/neck/skin folds
• Apply once or twice daily until inflammation is controlled
• After achieving control, transition to twice-weekly maintenance therapy to prevent relapses 2
• This proactive maintenance approach has strong evidence for reducing flare frequency

Essential Adjunctive Measures

• Liberal emollient use is mandatory - has both short and long-term steroid-sparing effects 1, 2
• Apply moisturizers at least twice daily, particularly after bathing
• Use two fingertip units of moisturizer for both hands 3
• Identify and avoid trigger factors (irritants, allergens, excessive heat/sweating) 1

Second-Line Topical Options

If TCS alone are insufficient or there are concerns about steroid side effects:

Topical Calcineurin Inhibitors (TCIs)

• Tacrolimus 0.03% or 0.1% ointment (strong recommendation) 2
• Pimecrolimus 1% cream for mild-to-moderate disease (strong recommendation) 2
• Particularly valuable for sensitive areas (face, neck, intertriginous zones) where TCS may cause atrophy
• Can be used twice weekly as proactive maintenance therapy 1

Newer Topical Agents

• Crisaborole ointment (PDE-4 inhibitor) - strong recommendation for mild-to-moderate AD 2
• Ruxolitinib cream (JAK inhibitor) - strong recommendation 2
• Tapinarof cream - strong recommendation per 2025 update 4
• Roflumilast cream - strong recommendation per 2025 update 4

When Topical Therapy Fails

Wet Wrap Therapy

• Consider wet-wrap therapy with TCS before advancing to systemic therapy 1
• Effective short-term treatment for moderate-to-severe disease
• Apply TCS, cover with damp layer, then dry layer overnight
• Use for 1-2 weeks maximum 1

Phototherapy

• Conditional recommendation as next step before systemic agents 5
• Multiple modalities effective: NB-UVB, BB-UVB, UVA
• Safe option for patients who cannot use or have failed topical therapy

Critical Pitfalls to Avoid

Do NOT use:

• Long-term topical antibiotics - increases resistance and sensitization risk 1
• Topical antihistamines - may cause contact dermatitis 1
• Prolonged high-potency TCS on face/neck - causes skin atrophy 1

Common mistakes:

• Inadequate emollient use - this is not optional, it's foundational
• Stopping TCS too quickly - transition to maintenance dosing rather than abrupt cessation
• Using dish detergent or hot water for hand washing - worsens barrier dysfunction 3
• Applying oil-based moisturizers under latex gloves - causes glove breakdown 3

Infection Management

• Only use systemic antibiotics if clinical signs of bacterial infection are present 1
• Consider bleach baths (dilute sodium hypochlorite) for recurrent infections, though evidence is mixed 2
• Intranasal mupirocin may reduce Staphylococcus aureus colonization in severe cases 1

When to Escalate

Consider systemic therapy if:

• Inadequate control despite optimized topical therapy
• Significant quality of life impairment
• Extensive body surface area involvement
• Phototherapy not feasible or failed

The 2024 AAD guidelines provide strong recommendations for dupilumab, tralokinumab, abrocitinib, baricitinib, and upadacitinib as systemic options 5, with biologics (dupilumab, tralokinumab) and JAK inhibitors preferred over traditional immunosuppressants.